Literature DB >> 14526452

Influence of different culture solutions on osteoblastic differentiation in cord blood and bone marrow derived progenitor cells.

M Jäger1, A Wild, S Lensing-Höhn, R Krauspe.   

Abstract

Mesenchymal progenitor cells derived from cord blood (unrestringated somatic stem cells, USSC) and bone marrow (mesenchymal stem cells, MSC) are able to differentiate under defined culture conditions into at least bone, cartilage, adipose and muscle cells in vitro. The culture media and other in vitro conditions influence the osteogenic differentiation potency of both cell types. To increase and expand the number of osteoblasts in vitro an optimization of culture conditions is required. The aim of this study was to evaluate different culture media toward their osteogenic promoting capacity on human USSCs and MSCs in vitro. Immunohistochemical stainings against osteonectin (ON), osteopontin (OP) served as markers for an osteoblastic differentiation. Cellular morphology was analysed by light microscopy technique. We found significant differences between bone marrow and cord blood derived stem cells towards an osteoblastic differentiation. Considering the number of osteoblasts MesenCult seems to have advantages in bone marrow progenitor cells, whereas low glucose DMEM and HAMS-F12 promoted an osteoblastic differentiation in cord blood derived cells more than other tested media.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526452     DOI: 10.1515/bmte.2003.48.9.241

Source DB:  PubMed          Journal:  Biomed Tech (Berl)        ISSN: 0013-5585            Impact factor:   1.411


  10 in total

1.  Proteomic analysis of proteins associated with cellular senescence by calorie restriction in mesenchymal stem cells.

Authors:  Hyun-Jung Kim; Bo-Ram Ji; Ji-Soo Kim; Han-Na Lee; Dong-Ho Ha; Chan-Wha Kim
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-03       Impact factor: 2.416

2.  Osteogenic and adipogenic differentiation potential of an immortalized fibroblast-like cell line derived from porcine peripheral blood.

Authors:  Xiuqing Wang; Daphne Moutsoglou
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-12       Impact factor: 2.416

Review 3.  Cord blood--an alternative source for bone regeneration.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe
Journal:  Stem Cell Rev Rep       Date:  2009-08-04       Impact factor: 5.739

Review 4.  [Cell therapy in bone-healing disorders].

Authors:  M Jäger; P Hernigou; C Zilkens; M Herten; J Fischer; R Krauspe
Journal:  Orthopade       Date:  2010-04       Impact factor: 1.087

5.  Induction of differentiation by down-regulation of Nanog and Rex-1 in cord blood derived unrestricted somatic stem cells.

Authors:  Lida Langroudi; Mehdi Forouzandeh; Masoud Soleimani; Amir Atashi; Azadeh Fahim Golestaneh
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

6.  [In vivo and in vitro bone regeneration from cord blood derived mesenchymal stem cells].

Authors:  M Jäger; M Sager; A Knipper; O Degistirici; J Fischer; G Kögler; P Wernet; R Krauspe
Journal:  Orthopade       Date:  2004-12       Impact factor: 1.087

7.  Cell therapy in bone healing disorders.

Authors:  Marcus Jäger; Philippe Hernigou; Christoph Zilkens; Monika Herten; Xinning Li; Johannes Fischer; Rüdiger Krauspe
Journal:  Orthop Rev (Pavia)       Date:  2010-09-23

Review 8.  O-GlcNAcylation: a bridge between glucose and cell differentiation.

Authors:  Chao Sun; Jin Shang; Yuan Yao; Xiaohong Yin; Minghan Liu; Huan Liu; Yue Zhou
Journal:  J Cell Mol Med       Date:  2016-03-01       Impact factor: 5.310

Review 9.  Autologous cell-based therapy for treatment of large bone defects: from bench to bedside.

Authors:  R Verboket; M Leiblein; C Seebach; C Nau; M Janko; M Bellen; H Bönig; D Henrich; I Marzi
Journal:  Eur J Trauma Emerg Surg       Date:  2018-01-19       Impact factor: 3.693

10.  99mTc-Hydroxydiphosphonate quantification of extracellular matrix mineralization in 3D human mesenchymal stem cell cultures.

Authors:  Tobias L Grossner; Uwe Haberkorn; Tobias Gotterbarm
Journal:  Bone Joint Res       Date:  2019-08-02       Impact factor: 5.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.